secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neurogene Inc. (NGNE)
CIK:        0001404644
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001404644-26-000006
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurogene's NGN-401 receives FDA Breakthrough Therapy designation for Rett syndrome
--------------------------------------------------------------------------------

- FDA granted Breakthrough Therapy designation for NGN-401, a gene therapy for Rett syndrome.
- Designation based on interim Phase 1/2 data showing clinically meaningful, durable multidomain improvements.
- Completion of dosing in Embolden registrational trial expected Q2 2026.
- Company plans to present additional interim Phase 1/2 data in mid-2026.
- NGN-401 also has RMAT, Rare Pediatric Disease designations; part of FDA START Pilot Program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404644/000140464426000006/0001404644-26-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404644/000140464426000006/ngne-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001404644-26-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer